安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Hydroxyurea in Sickle Cell Disease: Drug Review - PMC
Current evidence suggests that several potential mechanisms of action by hydroxyurea may be relevant for patients with SCA, which together lead not only to HbF induction but also to additional benefits
- Hydroxyurea Treatment for Sickle Cell Disease - PMC
Hydroxyurea promotes HbF production by perturbing the maturation of erythroid precursors This treatment increases the total hemoglobin concentration, reduces the vaso-occlusive complications of pain and acute chest syndrome, and attenuates mortality in adults
- Hydroxyurea for Sickle Cell Disease - American Society of Hematology
Treatment Information from the American Society of Hematology About the American Society of Hematology matologists conquer blood diseases With more than 17,000 members from nearly 100 countries, ASH is the world’s largest pr fessional society of hematologists We’re dedicated to furthering the understanding, diagnosis, treatment, and preventi
- Hydroxyurea’s Mechanism of Action for Sickle Cell Disease
Explore the detailed pharmacological pathway of Hydroxyurea, explaining how it modifies cellular processes to effectively treat Sickle Cell Disease
- The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia
Despite advancements in treatment of sickle cell disease (SCD), hydroxyurea, a ribonucleotide reductase inhibitor, remains the cornerstone of therapy While its primary effect is the elevation of fetal hemoglobin (HbF), hydroxyurea’s mechanisms of action are multifaceted
- Hydroxyurea use in sickle cell disease - UpToDate
Approaches that are available for reducing these pathophysiologic processes include regular red blood cell (RBC) transfusions and disease-modifying medications, especially hydroxyurea, which is the mainstay of pharmacologic therapy
- Hydroxyurea for Sickle Cell Disease
The main way that hydroxyurea treats sickle cell disease is by increasing your amount of fetal hemoglobin (HbF) This type of hemoglobin is normally only present in newborns, and it protects them from complications of SCD
- Hydroxyurea and Transfusion Therapy - American Society of Hematology
Its primary mechanism of action is induction of fetal hemoglobin Treatment benefits include reduced frequency of acute sickle cell pain and acute chest syndrome, reduced need for blood transfusions and hospitalizations, and possibly improved survival
|
|
|